But CRISPR is a long-term story that is still in the early innings. The company has moved past its proof-of-concept phase, ...

Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...

Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...

EDEN (short for environmentally-derived evolutionary network) processes evolutionary DNA from more than one million newly ...

A golden apple snail can regrow a complete camera-type eye in 30 days, offering new clues into genetic pathways that may one day help restore human vision ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...

Faced with a life-threatening metabolic disease, KJ’s doctors at Children’s Hospital of Philadelphia sprinted to create a ...